贝达药业 (300558.SZ) Latest Company News

Sep 3, 2026, 07:51 UTC
Betta Pharmaceuticals announced that China's National Medical Products Administration issued a drug registration certificate for ensartinib capsules (brand name: Benmeina), approving a new indication for adjuvant treatment of ALK-positive stage IB to IIIB non-small cell lung cancer after surgery, the third approved indication for ensartinib.
Source:
- finance.sina.cn
Aug 21, 2026, 15:43 UTC
Betta Pharmaceuticals held a conference call on August 21, 2026 to discuss its 2026 half-year results, reporting revenue of 1.976 billion yuan, up 14% year-on-year.
Source:
- wap.eastmoney.com
Aug 18, 2026, 03:34 UTC
On August 18, 2026, Betta Pharmaceuticals' shares plunged 20% to the daily limit in early trading, following a sharp decline in the US stock EyePoint Pharmaceuticals after its Phase III trial failed to meet the primary endpoint.
Source:
- finance.ifeng.com
Aug 10, 2026, 11:06 UTC
Shareholder Hangzhou Teruixichuang Enterprise Management Partnership reduced 495,900 shares of Betta Pharmaceuticals through centralized bidding trading from May 8 to August 7, 2026, accounting for 0.1171% of total share capital at an average price of 69.99 yuan per share, and the reduction plan period has expired.
Source:
- finance.sina.cn
Jul 17, 2026, 07:50 UTC
Betta Pharma received approval from the National Medical Products Administration for a clinical trial of Icotinib Hydrochloride Tablets (Conmana) for postoperative adjuvant treatment of IA2 high-risk to stage IB EGFR-mutant non-small cell lung cancer.
Source:
- finance.sina.cn
Jul 10, 2026, 10:35 UTC
China's National Health Commission and multiple departments published the 2026 edition of the National Essential Drugs List, which includes three drugs from Betta Pharma: bevacizumab (newly added), icotinib, and trastuzumab (both continued from the 2018 edition).
Source:
- finance.sina.cn
Jul 9, 2026, 00:15 UTC
Betta Pharma's clinical study on ensartinib (Bemena) as adjuvant therapy for ALK-positive NSCLC was published online in the New England Journal of Medicine.
Source:
- finance.sina.cn

300558.SZ

Betta Pharmaceuticals held a conference call on August 21, 2026 to discuss its 2026 half-year results, reporting revenue of 1.976 billion yuan, up 14% year-on-year.

On August 18, 2026, Betta Pharmaceuticals' shares plunged 20% to the daily limit in early trading, following a sharp decline in the US stock EyePoint Pharmaceuticals after its Phase III trial failed to meet the primary endpoint.

Betta Pharma received approval from the National Medical Products Administration for a clinical trial of Icotinib Hydrochloride Tablets (Conmana) for postoperative adjuvant treatment of IA2 high-risk to stage IB EGFR-mutant non-small cell lung cancer.

China's National Health Commission and multiple departments published the 2026 edition of the National Essential Drugs List, which includes three drugs from Betta Pharma: bevacizumab (newly added), icotinib, and trastuzumab (both continued from the 2018 edition).

Betta Pharma's clinical study on ensartinib (Bemena) as adjuvant therapy for ALK-positive NSCLC was published online in the New England Journal of Medicine.